Cardiac Monitoring News
-
Implicity Joins the AWS ISV Accelerate Program
Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program, a co-sell program for AWS partners that provide software solutions that run on or integrate with AWS. The program helps AWS partners drive new business by directly connecting participating ISCs with the ...
By Implicity
-
Medicalgorithmics Announces Hiring of Medical Device Commercial Veteran James Landis as Vice President Sales and Business Development of North America
Medicalgorithmics a Warsaw Stock Exchange listed medical technology company, is boosting its sales capabilities in North America with appointment of James Landis as the new Vice President of Sales and Business Development for North America. The move is aimed at accelerating long-term growth and increasing market share in the US. James brings 20 years of extensive experience in sales and ...
-
William A. (Bill) Breukelman Named to CardioWise, Inc. Board of Directors
An internationally recognized entrepreneur, Mr. Breukelman is a pioneer in imaging technology, initially as principal and chairman of IMAX Corporation, followed by significant transformative contributions to medical and scientific research companies in information technology and strategic development. Jack Coats, Chief Executive Officer of CardioWise, Inc., announced that Mr. William A. ...
-
Bodyport Appoints Amit Rushi as Chief Commercial Officer and Phyllis Whiteley, Ph.D. as Chair of the Board of Directors
Bodyport, the digital health company focused on the detection and management of heart disease, today announced that it has named Amit Rushi as Chief Commercial Officer (CCO) and Phyllis Whiteley as Chair of the Board of Directors. With this newly created role, Amit Rushi will serve as part of the executive team and prepare the organization for commercialization and growth. As Chair of the Board, ...
-
Novel Modulators of LDL Metabolism
DESCRIPTION provided by applicant Heart disease is the leading cause of death for both men and women in the US accounting for nearly of all annual deaths A high cholesterol level is well known risk factors for heart disease Although blood cholesterol can be lowered using a number of marketed drugs of which statins are the leading drugs only of patients taking these drugs are achieving the low ...
-
Results of Four Studies Demonstrating Clinical, Economic Value of iRhythm’s Product Portfolio Presented at American Heart Association ’22
iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading cardiovascular diagnostics and digital healthcare solutions company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the results of four clinical studies presented at the American Heart Association’s (AHA) 2022 Scientific Sessions in Chicago, IL. The studies demonstrate health economic and ...
-
Elucid Appoints Dr. Michael Lesh to Board of Directors
BOSTON, November 3, 2022 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Michael D. Lesh, MD, FACC, to its Board of Directors. “We look forward to what Dr. Lesh will bring to the board with his extensive background as a cardiologist, medtech ...
By Elucid
-
iRhythm announces results of four studies to be unveiled at American Heart Association Scientific Sessions
iRhythm Technologies will have the results of four studies presented by leading clinical investigators at the American Heart Association’s 2022 Scientific Sessions on Nov. 5-7 in Chicago, Illinois. The studies listed below focus on iRhythm’s core suite of Zio XT and AT patch-based extended and mobile cardiac monitoring products and services. Saturday, Nov. 5 3:00 – 4:00 p.m. ...
-
Biotricity surpasses 2 billion recorded and analyzed heartbeats for atrial fibrillation (AFib)
Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced a significant milestone of recording and analyzing over 2 billion heartbeats for Atrial Fibrillation (AFib), the most common type of cardiac arrhythmia and a leading cause of stroke. Bioflux®, Biotricity’s ...
-
Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
– New Data Further Support Potential for Patisiran to be an Effective Treatment for Cardiomyopathy of ATTR Amyloidosis – – Data from Exploratory Endpoints, Including Cardiac Biomarkers and Imaging, Suggest Favorable Impact of Patisiran on Measures of Cardiac Stress, Injury, Structure, and Function at Month 12 – – Treatment with Patisiran Demonstrated Generally ...
-
Pro-PLUS cardiomonitoring for young patients of Children’s Hospital in Bialystok
Cardiac arrhythmias affect not only adults, but unfortunately also children struggle with such health problems. It is for little patients that the K.I.D.S. Foundation announced a competition "Telemedicine in Children's Hospitals of the Future". One of the winning projects of this competition is the project "TeleFriends from the Heart" submitted by the University Children's Hospital in Bialystok, ...
By Pro-PLUS SA
-
Biotricity wins NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure
Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that it will be carrying out an NIH-sponsored Phase I study of Bioflux-AI, Biotricity’s innovative artificial intelligence-driven (‘AI’) system of real-time monitoring and prediction technology, in subjects with ...
-
GE Healthcare in collaboration with Nex Cubed select six digital health start-ups for inaugural Edison Accelerator in Canada
Six digital health start-ups from five countries have officially become the first cohort of the Edison Accelerator in Canada – a program designed by GE Healthcare and delivered in collaboration with Nex Cubed to accelerate, validate, and scale innovative solutions that address important challenges in the healthcare sector. The companies all focus on applying Artificial Intelligence (AI) to ...
-
Bodyport Receives FDA Clearance for the Bodyport Cardiac Scale
Bodyport, a digital therapeutics company on a mission to address complex chronic conditions, announced today that its noninvasive biomarker platform, the Bodyport Cardiac Scale™ received U.S. Food & Drug Administration (FDA) 510(k) clearance. This innovative solution enables people with fluid management conditions, such as heart failure and kidney disease, to noninvasively assess ...
-
CardioWise™ Receives ISO 13485:2016 Clearance for Design, Development, and Marketing of Software as a Medical Device (SaMD) For the Medical Device Industry
CardioWise, Inc., is pleased to announce that Perry Johnson Registrars, Incorporated has audited the CardioWise Quality Management System (QMS) and determined CardioWise is in conformance with ISO 13485:2016. Perry Johnson Registrars Certificate C2022-02910 was issued July 16, 2022, and represents the first step in the process of obtaining a CE mark and Medical Device Registration for the ...
-
BioSerenity, Inc. appoints new leadership in North America
BioSerenity, a high-growth company specializing in research and remote diagnostic solutions for neurology, sleep medicine, and cardiology, announces Jeff Wren’s appointment as Chief Executive Officer of North America. Jeff Wren assumes the leadership role in the states as Pierre Frouin, CEO of BioSerenity, moves back to Europe. Since its expansion to the United States in 2019, ...
By BioSerenity
-
Assessing Heart Function and Fluid Status with Cardiac Scales: Interview with John Lipman, CEO, and Corey Centen, Founder, Bodyport
Bodyport, a medtech company based in San Francisco, developed the Bodyport Cardiac Scale, a set of weighing scales that can non-invasively assess fluid status and heart function. The scales can detect these signals through the feet when a patient steps onto the device. The technology is intended to be convenient and requires only 20 seconds each morning, and should easily lend itself to ...
-
FAPI featured in accolades at annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting
Congratulations to investigators at Hannover School of Medicine and Heidelberg University Hospital for receiving the 2022 SNMMI Image of the Year Award and JNM Editors’ Choice Award for Overall Best Article in 2021, respectively. Both use FAPI as the primary indicator and further underscore its potential impact as a novel radiopharmaceutical. Each year, SNMMI chooses an image that best ...
By SOFIE
-
TeraRecon Announces DocPanel Signs Contract for Intuition Titanium, Reaffirming its Cardiothoracic Imaging Service Commitment
TeraRecon, a ConcertAI company and a leader in advanced medical visualization using AI to improve patient care, today announced U.S.-based DocPanel, the world’s first radiology marketplace offering access to over 500 fellowship trained radiologists available for radiological reads, second opinions, and educational consults, has signed a contract for TeraRecon’s advanced visualization ...
-
iRhythm builds case for wearable cardiac monitor with data in fainting, TAVR patients
iRhythm Technologies has presented new data on its Zio wearable cardiac monitoring device at the American College of Cardiology (ACC) 71st Annual Scientific Session & Expo, building the clinical case for its devices. One study used Zio AT for monitoring patients who were taken to hospital after fainting. By using the device to monitor patients after discharge, the physicians reduced ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you